GlaxoSmithKline PLC’s alli recall places patient safety ahead of sales in a way that could mitigate long-term damage to the weight-loss drug’s reputation, just as Johnson & Johnson did in its response to tampering with Tylenol in the 1980s.
Alli Recall Could Help Mitigate Reputation Damage In Face Of Tampering
GSK investigates tampering with its alli weight-loss drug and positions itself as a consumer advocate with a U.S. recall of the product. By showing it is “on the side of good” the firm could actually emerge from the crisis with a stronger reputation, says crisis management expert Gene Grabowski says.
More from United States
More from North America
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
Former Acting FDA Commissioner Sara Brenner is said to have asked Tracy Beth Høeg, new special assistant to the commissioner, to help reexamine the application. Høeg’s position at the agency is raising concerns about the FDA's ongoing approach to vaccine regulation.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?